1) zur Hausen H. Papillomavirus and cancer : from basic studies to clinical application. Nat Rev Cancer 2002 ; 2 : 342-50.
2) You J. Papillomavirus interaction with cellular chromatin. Biochim Biophys Acta 2010 ; 1799 : 192-9.
3) Bosch FX, de Sanjose S. Human papillomavirus and cervical cancer : burden and assessment of causality. J Natl Cancer Inst Monogr 2003 ; (31) : 3-13.
4) Ho GY, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998 ; 338 : 423-8.
5) 川名敬ほか. STDは子宮頸がん・外陰がんを増加させているか? 産科と婦人科2003 ; 70 : 1173-9.
6) Inoue M, et al. The evaluation of human papillomavirus DNA testing in primary screening for cervical lesions in a large Japanese population. Int J Gynecol Cancer 2006 ; 16 : 1007-13.
7) Frazer I, Vaccine Development Team. The current status of development of prophylactic vaccines against human papillomavirus infection. Report of a technical meeting. Geneva : WHO ; 16-18 February, 1999.
8) Miura S, et al. Do we need a different strategy for HPV screening and vaccination in East Asia? Int J Cancer 2006 ; 119 : 2713-5.
9) Franco EL, et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 1999 ; 180 : 1415-23.
10) Holowath P, et al. Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst 1999 ; 91 : 252-8.
11) Matsumoto K, et al. Japan HPV And Cervical Cancer Study Group. Predicting the progression of cervical precursor lesions by human papillomavirus genotyping : a prospective cohort study. Int J Cancer 2011 ; 128 : 2898-910.
12) Furuta R, et al. Ectopic chromosome around centrosome in metaphase cells as a marker of high-risk human papillomavirus-associated cervical intraepithelial neoplasias. Int J Cancer 2003 ; 106 : 167-71.
13) Mirkovic J, et al. Carcinogenic HPV infection in the cervical squamo-columnar junction. J Pathol 2015 ; 236 : 265-71.
14) Hu Z, et al. Genome-wide profiling of HPV integration in cervical cancer identifies clustered genomic hot spots and a potential microhomology-mediated integration mechanism. Nat Genet 2015 ; 47 : 158-63.
15) Kukimoto I, et al. Hypermutation in the E2 gene of human papillomavirus type 16 in cervical intraepithelial neoplasia. J Med Virol 2015 ; 87 : 1754-60. doi : 10.1002/jmv.24215.
16) Sato M, et al. Regeneration of cervical reserve cell-like cells from human induced pluripotent stem cells (iPSCs) : a new approach to finding targets for cervical cancer stem cell treatment. Oncotarget 2017 ; 8 : 40935-45.
17) Nishida H, et al. Systemic delivery of siRNA by actively targeted polyion complex micelles for silencing the E6 and E7 human papillomavirus oncogenes. J Control Release 2016 ; 231 : 29-37.
18) Ikeda Y, et al. Safety and efficacy of mucosal immunotherapy using human papillomavirus (HPV) type 16 E7-expressing Lactobacillus-based vaccine for the treatment of high-grade squamous intraepithelial lesion (HSIL) : the study protocol of a randomized placebo-controlled clinical trial (MILACLE study). Jpn J Clin Oncol 2019 ; 49 : 877-80.